CVRx®

August 2026

NASDAQ: CVRX

CVRx
Outsmart the heart

Disclaimer

Cautionary Note Regarding Forward-Looking Statements

This presentation by CVRx, Inc. (the "Company") contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements, including statements regarding our future financial performance (including, specifically, our 2026 expected operating and financial results), our anticipated growth strategies, anticipated trends in our industry, our business prospects and our opportunities. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "outlook," "guidance," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words.

The forward-looking statements in this presentation are only predictions and are based largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this presentation and are subject to a number of known and unknown risks, uncertainties and assumptions, including, but not limited to, our history of significant losses, which we expect to continue; our limited history operating as a commercial company and our dependence on a single product, Barostim; our limited commercial sales experience marketing and selling Barostim; our ability to continue demonstrating to physicians and patients the merits of our Barostim; any failure by third-party payors to provide adequate coverage and reimbursement for the use of Barostim; our competitors' success in developing and marketing products that are safer, more effective, less costly, easier to use or otherwise more attractive than Barostim; any failure to receive access to hospitals; our dependence upon third-party manufacturers and suppliers, and in some cases a limited number of suppliers; a pandemic, epidemic or outbreak of an infectious disease in the U.S. or worldwide; the constant growth and development of technology, including artificial intelligence; product liability claims; future lawsuits to protect or enforce our intellectual property, which could be expensive, time consuming and ultimately unsuccessful; any failure to retain our key executives or recruit and hire new employees; impacts on adoption and regulatory approvals resulting from additional long-term clinical data about our product, including those resulting from the BENEFIT-HF clinical trial; and other important factors that could cause actual results, performance or achievements to differ materially from those that are found in "Part I, Item 1A. Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2025, as such factors may be updated from time to time in our other filings with the Securities and Exchange Commission. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Market & Industry Data

This presentation includes market and industry data and forecasts that the Company has developed from independent research reports, publicly available information, various industry publications, other published industry sources or the Company's internal data and estimates. Independent research reports, industry publications and other published industry sources generally indicate that the information contained therein was obtained from sources believed to be reliable, but do not guarantee the accuracy and completeness of such information. Although the Company believes that the publications and reports are reliable, the Company has not independently verified the data and makes no representation or warranty with respect to the accuracy of such information.

CVRx is commercializing the world's first autonomic neuromodulation therapy to improve heart failure symptoms

Implantable Pulse Generator (IPG) & Carotid Sinus Lead

Wireless Programmer



CVRx
Outsmart the heart

Barostim addresses a significant unmet need in the HF treatment continuum



1. Adapted from Greenhalgh et al. BMC Cardiovascular Disorders (2017) 17:156.
2. Heidenreich PA, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Circulation.
3. Estep et al. Journal of Cardiac Failure (2024) 30:11. 1472-1488. GDMT = Guideline-Directed Medical Therapy.

CVRx
Outsmart the heart

We are less than 2% penetrated into a $10.5B U.S. net addressable market for Barostim*



	Prevalence	Incidence
General HF Population	6.7M	1.3M
NYHA II/III with EF ≤ 35%	1.3M	290K
NT-proBNP <1600pg/mL	679K	156K
Not indicated for CRT and suitable for surgery	339K	76K
	$10.5B	$2.4B

(Assumes $31K ASP)

* Note: We estimate our total market opportunity using both prevalence and incidence epidemiologic models in which prevalence reflects the total number of individuals indicated for therapy at a given time, while incidence captures the annual occurrence of new cases meeting the indication. The $10.5B market opportunity reflects the prevalence-based model for the U.S. Heart Failure with reduced Ejection Fraction (HFrEF) market. These estimates are based on an Internal CVRx Market Model

Our revised go-to-market strategy launched in late 2024 is focused on driving Barostim to become Standard of Care for HFrEF

Three Key Strategies

1

Improve salesforce productivity

2

Drive deep adoption in targeted centers

3

Address the barriers to adoption

- Patient Access
- Awareness
- Evidence

CVRx
Outsmart the heart

Our program selling strategy is focused on aligning stakeholders and creating a workflow that facilitates consistent utilization and deep adoption



CVRx
Outsmart the heart

We have made significant progress against the three barriers to adoption for Barostim Therapy since launching our revised strategy in late 2024

PATIENT ACCESS

- ✓ **CAT I effective Jan 1, 2026**
- ✓ **Traditional Medicare Outpatient Claims^**



- ✓ **Medicare Advantage 30 Day Approval***



AWARENESS



CRF THT
HFSA
ISHLT
AAHFN

EVIDENCE

BENEFIT HF

^ - Traditional Medicare outpatient claims data is based on the published data from calendar year 2025
* - Medicare Advantage 30-Day approval rates on based on internal data from the second quarter of 2026

CVRx
Outsmart the heart

NCT07232030

BENEFIT-HF

A landmark heart failure trial evaluating Barostim™ in a significantly expanded population

Expected to be one of the largest therapeutic cardiac device trials ever performed in heart failure



Population

Expanded population to EF<50% & NT-proBNP 400 - 5000 pg/mL

Trial Size

2,500 patients randomized across ~150 centers in the U.S. & Germany

Endpoints

Primary composite endpoint of all-cause mortality, LVAD, transplant, and hospitalization events

Coverage

Supported by CMS Category B IDE Coverage



Duration

2-year follow-up (enrollment expected 1H 2026 to 2030)

Indication: The Barostim System is FDA-approved and indicated for patients who are NYHA Class III or Class II (who had a recent history of Class III) despite treatment with guideline-directed medical therapies (medications and devices), have a left ventricular ejection fraction of ≤ 35%, and a NT-proBNP <1600 pg/mL. Barostim delivers Baroreflex Activation Therapy for improvement of patients' heart failure functional status, six-minute hall walk, and quality of life.

Investigational Use: BENEFIT-HF is a clinical trial evaluating Barostim in an expanded heart failure population for whom safety and effectiveness have not yet been established. Barostim is not FDA-approved for use in this expanded patient population.

CVRx
Outsmart the heart

Recently implemented Category I Codes and the first Medicare Advantage policy (Humana) for Barostim are steadily improving patient access

Payer Mix of Barostim-Eligible Patients



Positive impact of coverage policy

All MACs are processing claims; 97% of submitted outpatient claims have been paid*

Cat I creates opportunity with TRICARE & Medicaid who do not cover Cat III codes

Cat I Removes automatic Cat III denial policy for ~50% of commercial payers

1. KFF analysis of CMS Medicare Advantage enrollment files, 2025–2026. "Medicare Advantage Enrollment Grew by About 1 Million People, Mainly Due to Special Needs Plans." KFF, March 2026. *Data from CY25 Q1-Q4 SAF.

CVRx Outsmart the heart

CVRx®

Outsmart the heart

NASDAQ: CVRX

World's first autonomic neuromodulation therapy to improve heart failure symptoms

- **$10.5B market** opportunity with significant adjacent markets
- **Differentiated** therapy with a compelling safety profile and high response rate
- **Well-defined patient population** with limited treatment options
- **Focused plan** to drive Barostim therapy to standard of care

Safe
Procedure

Effective
Significant QoL benefit

Durable
Therapy out to 2 years

Recent Milestones

- CMS — New Category I CPT Codes (Jan 1, 2026)
- BENEFIT HF — Clinical Trial Launch (Jan 22, 2026)
- Humana — Med. Advantage Coverage Policy (May 14, 2026)

Contact

Address: 9201 Broadway #650, Minneapolis, MN 55445

Website: www.ir.cvrx.com

Email: ir@cvrx.com